US FDA concludes SMS Pharma’s inspection with zero observation

The ‘Central Laboratory Analytical Services’ is our independent testing laboratory, and this was the first USFDA inspection concluded with zero observations, it added.

SMS Pharma has successfully completed regulatory inspection by the United States Food and Drug Administration (US FDA) at its exclusive testing facility.

The company said, "The successful completion of regulatory inspection by the United States Food and Drug Administration (US FDA) for our exclusive testing facility, SMS Pharmaceuticals (Central Laboratory Analytical Services) during March 2-6, 2020. The regulatory audit resulted in zero observation."

The company is committed to meeting the highest quality standards and is further committed to full compliance with CGMP & GLP regulations at all its manufacturing and analytical facilities.

The ‘Central Laboratory Analytical Services’ is the company’s independent testing laboratory, and this was the first US FDA inspection concluded with zero observations, it added.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.